Global Phase 3 Trial of AMX0035 to Enroll 600 ALS Patients, Amylyx Says

Global Phase 3 Trial of AMX0035 to Enroll 600 ALS Patients, Amylyx Says

294269

Global Phase 3 Trial of AMX0035 to Enroll 600 ALS Patients, Amylyx Says

A global Phase 3 trial of AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS)  intends to enroll up to 600 patients, the therapy’s developer, Amylyx Pharmaceuticals, announced in a press release. Likely to be initiated in the coming months, the trial — to be called PHOENIX — will be take place at 55 sites across the U.S. and Europe, the result of a collaboration between the Northeast ALS Consortium (NEALS) and the Treatment Research…

You must be logged in to read/download the full post.